biovaxys technology

biovaxys technology

CNSX:BIOV
BioVaxys Technology Corp.

Chart

Detailed Quote

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

Featured Articles and Interviews
Press Releases

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

The Conversation (0)